The need for early markers in Alzheimer’s disease

  • D. L. Murphy
  • T. Sunderland
Part of the New Vistas in Drug Research book series (DRUG RESEARCH, volume 1)


Currently, there are no definitive early markers for Alzheimer’s disease (AD) or senile dementia of the Alzheimer type (SDAT). Nonetheless, there are some interesting marker candidates under evaluation. Several examples of candidate markers are considered in this review, including some biochemical, genetic, pharmacological, neuroimaging, and clinical measures. These examples are chosen to illustrate some aspects of an ideal marker, as well as the needs for such markers in different areas of AD and SDAT research and treatment.


Single Photon Emission Compute Tomography Alzheimer Patient Discriminant Function Analysis Cerebral Blood Flow Measurement Elderly Depressed Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aigner TG, Mitchell SJ, Aggleton JP, DeLong MR, Struble RG, Price DL,Wenk GL, Mishkin M (1987) Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. Psychopharmacology 92: 292–300Google Scholar
  2. Barclay L (1988) Differential diagnosis of dementing diseases. Age 11: 19–22CrossRefGoogle Scholar
  3. Beal MF, Growdon JH, Mazurek MF, Martin JB (1986) CSF somatostatinlike immunoreactivity in dementia. Neurology 36: 294–297PubMedGoogle Scholar
  4. Berg L (1985) Does Alzheimer’s disease represent an exaggeration of normal aging? Arch Neurol 42: 737–739PubMedCrossRefGoogle Scholar
  5. Brayne C, Calloway P (1988) Normal ageing, impaired cognitive function, and senile dementia of the Alzheimer’s type: a continuum? Lancet is 1265–1267Google Scholar
  6. Brody JA (1982) An epidemiologist views senile dementia: facts and fragments. Am J Epidemiol 115: 155–162PubMedGoogle Scholar
  7. Chakravarti A, Slaugenhaupt SA, Zubenko GS (1989) Inheritance pattern of platelet membrane fluidity in Alzheimer’s disease. Am J Hum Genet 44: 799–805PubMedGoogle Scholar
  8. Clark DC, Clayton PS, Andreasen NC, Lewis C, Fawcett J, Scheftner WAK (1985) Intellectual functioning and abstraction ability in major affective disorders. Compr Psychiatry 26: 313–325PubMedCrossRefGoogle Scholar
  9. Cutler NR (1988 a) Utility of biologic markers in the evaluation and diagnosis of Alzheimer’s disease. Brain Dysfunction 1: 12–31Google Scholar
  10. Cutler NR (1988 b) Recent advances in the development of ante-mortem diagnostic markers for Alzheimer’s disease. Curr Opin Psychiatry 1: 462–467CrossRefGoogle Scholar
  11. Davies P (1988) Neurochemical studies: an update on Alzheimer’s disease. J Clin Psychiatry 49 [Suppl 5]: 23–28PubMedGoogle Scholar
  12. Davies P, Maloney AJR (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet ii: 1403–1405Google Scholar
  13. Davis KL, Davidson M, Yang RK, Davis BM, Siever LJ, Mohs RC, Ryan T, Coccaro E, Bierer L, Targum SD (1988) CSF somatostatin in Alzheimer’s disease, depressed patients, and control subjects. Biol Psychiatry 24: 710–712PubMedCrossRefGoogle Scholar
  14. Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. Arch Neurol 30: 113–121PubMedCrossRefGoogle Scholar
  15. Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y (1987) Cholinergic-dependent cognitive deficits in Parkinson’s disease. Ann Neurol 22: 26–30PubMedCrossRefGoogle Scholar
  16. Friedland RP, Brun A, Budinger TF (1985 a) Pathological and positron emis- sion tomographic correlations in Alzheimer’s disease. Lancet is 228Google Scholar
  17. Friedland RP, Budinger TF, Koss E, Ober BA (1985 b) Alzheimer’s disease: anterio-posterior and lateral hemispheric alterations in cortical glucose utilization. Neurosci Lett 53: 235–240PubMedCrossRefGoogle Scholar
  18. Friedland RP, Koss E, Haxby JV, Grady CL, Luxenberg J, Schapiro MB, Kaye J (1988) Alzheimer’s disease: clinical and biological heterogeneity. Ann Intern Med 109: 298–311PubMedGoogle Scholar
  19. Funsch D, Sunderland T, Lawlor BA, Molchan SE, Mellow AM, Tariot PN, Hill JL, Murphy DL (1989) Platelet MAO activity in Alzheimer patients, older depressives, and age-matched controls. Society of Biological Psychiatry, San Francisco, CA (Abstract )Google Scholar
  20. Gottfries CG (1985) Alzheimer’s disease and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology 86: 245–252PubMedCrossRefGoogle Scholar
  21. Hachinski VC, Lassen NA, Marshall J (1974) Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet ii: 207–210CrossRefGoogle Scholar
  22. Hollander E, Mohs RC, Davis KL (1986) Antemortem markers of Alzheimer’s disease. Neurobiol Aging 7: 367–387PubMedCrossRefGoogle Scholar
  23. Holman BL, Gibson RE, Hill TC, Eckelman WC, Albert M, Reba RC (1985) Muscarinic acetylcholine receptors in Alzheimer’s disease: in vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography. JAMA 254: 3063–3066PubMedCrossRefGoogle Scholar
  24. Kuhl DE, Small GW, Riege WH, Fujikawa DG, Metter EJ, Benson DF, Ashford JW, Mazziotta JC, Maltese A, Dorsey DA (1987) Abnormal PET-FDG scans in early Alzheimer’s disease. J Nucl Med 28: 645 (Abstract)Google Scholar
  25. Lawlor BA, Sunderland T, Mellow AM, Hill JL, Molchan SE, Murphy DL (1989 a) Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer’s disease: a controlled study. Arch Gen Psychiatry 46: 542–549PubMedCrossRefGoogle Scholar
  26. Lawlor BA, Sunderland T, Mellow AM, Hill JL, Newhouse PA, Murphy DL (1989 b) A preliminary study of the effects of intravenous m-chlorophenylpiperazine, a serotonin agonist, in elderly subjects. Biol Psychiatry 25: 679–686PubMedCrossRefGoogle Scholar
  27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA work group. Neurology 34: 939–944PubMedGoogle Scholar
  28. Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL (1988) Intravenous nicotine in Alzheimer’s disease: a pilot study. Psychopharmacology 95: 171–75PubMedCrossRefGoogle Scholar
  29. Perry E (1988) Acetylcholine and Alzheimer’s disease. Br J Psychiatry 152: 737–740PubMedCrossRefGoogle Scholar
  30. Post F (1975) Dementia, depression, and pseudo-dementia. In: Benson DF, Blumer D (eds) Psychiatric aspects of neurologic disease. Grune and Stratton, New York, pp 99–120Google Scholar
  31. Prohovnik I, Mayeux R, Sackeim HA, Smith G, Stern Y, Alderson PO (1988) Cerebral perfusion as a diagnostic marker of early Alzheimer’s disease. Neurology 38: 931–937PubMedGoogle Scholar
  32. Reifler BV, Larson E, Hanley R (1982) Coexistence of cognitive impairment and depression in geriatric outpatients. Am J Psychiatry 139: 623–626PubMedGoogle Scholar
  33. Risberg J, Gustafson L (1983) Xe cerebral blood flow in dementia and in neuropsychiatry research. In: Magistretti P (ed) Functional radionuclide imaging of the brain. Raven Press, New YorkGoogle Scholar
  34. Ron MA, Toone BK, Garralda ME, Lishman WA (1979) Diagnostic accuracy in presenile dementia. Br J Psychiatry 134: 161–168PubMedCrossRefGoogle Scholar
  35. Roy BF, Sunderland T, Dauphin MM, Goodman A, Frazier JS, Murphy DL, Morihisa JM (in press) Human antibody to nerve growth factor: a preliminary study with implications for Alzheimer’s disease. Ann NeurolGoogle Scholar
  36. Schneider LS, Severson JA, Chui HC, Pollock VE, Sloane RB, Fredrickson ER (1988) Platelet tritiated imipramine binding and MAO activity in Alzheimer’s disease patients with agitation and delusions. Psychiatry Res 25: 311–322PubMedCrossRefGoogle Scholar
  37. Sunderland T, Rubinow DR, Tariot PN, Cohen RM, Newhouse PA, Mellow AM, Mueller EA, Murphy DL (1987) CSF somatostatin in patients with Alzheimer’s disease, older depressed patients, and age-matched control subjects. Am J Psychiatry 144: 1313–1316PubMedGoogle Scholar
  38. Sunderland T, Tariot PN, Newhouse PA (1988) Differential responsivity of mood, behaviour, and cognition to cholinergic agents in elderly neuropsychiatrie populations. Brain Res Rev 13: 371–389CrossRefGoogle Scholar
  39. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, Grafman JH (1989) Clock drawing in Alzheimer’s disease: a novel measure of dementia severity. J Am Geriatr Soc 37: 725–729PubMedGoogle Scholar
  40. Tabaton M, Whitehouse PJ, Perry G, Davies P, Autilio-Gambetti L, Gambetti P (1988) Alz 50 recognizes abnormal filaments in Alzheimer’s disease and progressive supranuclear palsy. Ann Neurol 24: 407–413PubMedCrossRefGoogle Scholar
  41. Tanzi RE, St George-Hyslop PH, Gusella JF (1989) Molecular genetic approaches to Alzheimer’s disease. Trends Neurosci 12: 152–158PubMedCrossRefGoogle Scholar
  42. Tariot PN, Cohen RM, Welkowitz JA, Sunderland T, Newhouse PA, Murphy DL, Weingartner H (1988) Multiple-dose arecoline infusions in Alzheimer’s disease. Arch Gen Psychiatry 45: 901–905PubMedCrossRefGoogle Scholar
  43. Thal L (1988) Dementia update: diagnosis and neuropsychiatric aspects. J Clin Psychiatry 49 [Suppl 5]: 5–7PubMedGoogle Scholar
  44. Thienhaus OJ, Hartford JT, Skelly MF, Bosmann HB (1985) Biologic markers in Alzheimer’s disease. J Am Geriatr Soc 33: 715–726PubMedGoogle Scholar
  45. Wade JPH, Mirsen TR, Hachinski VC, Fisman M, Lau C, Merskey H (1987) The clinical diagnosis of Alzheimer’s disease. Arch Neurol 44: 24–29PubMedCrossRefGoogle Scholar
  46. Wells CE (1979) Pseudodementia. Am J Psychiatry 136: 895–900Google Scholar
  47. Weinberger DR, Gibson RE, Coppola R, Jones DW, Berman KF, Braun AR, Zeeberg BR, Sunderland T (1989) 123IodoQNB SPECT in Alzheimer’s and Pick’s diseases. American Psychiatric Association, San Francisco, CA (Abstract )Google Scholar
  48. Wolozin B, Davies P (1987) Alzheimer-related neuronal protein A 68: specificity and distribution. Ann Neurol 22: 521–526PubMedCrossRefGoogle Scholar
  49. Wolozin BL, Pruchnicki A, Dickson DW, Davies P (1986) A neuronal antigen in the brains of Alzheimer patients. Science 232: 648–650PubMedCrossRefGoogle Scholar
  50. Zubenko GS, Cohen BM, Boller F, Malinakova I, Keefe N, Chojnacki B (1987) Platelet membrane abnormality in Alzheimer’s disease. Ann Neurol 22: 237–244PubMedCrossRefGoogle Scholar
  51. Zubenko GS, Huff FJ, Beyer J, Auerbach J, Teply I (1988) Familial risk of dementia associated with a biologic subtype of Alzheimer’s disease. Arch Gen Psychiatry 45: 889–893PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1990

Authors and Affiliations

  • D. L. Murphy
    • 1
  • T. Sunderland
    • 1
  1. 1.Laboratory of Clinical ScienceNational Institute of Mental HealthBethesdaUSA

Personalised recommendations